Jenna Johnston1, Catherine Orrell2, Peter Smith1, Anton Joubert1, Lubbe Wiesner1. 1. Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa. 2. Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
RATIONALE: Drug levels in hair provide a longer window of detection, compared to plasma drug levels, and therefore hair analysis has the advantage of assessing adherence over a longer period of time. No methods for the analysis of antiretroviral drugs in hair currently exist in South Africa, and worldwide there is only one validated method for the determination of efavirenz in hair that has been published. METHODS: Efavirenz was extracted from 0.2 mg of hair through a simultaneous pulverization and extraction step. Separation was achieved on an Agilent Poroshell C18 column using an isocratic elution with a total run time of 3 min. A triple quadrupole mass spectrometer set to electrospray ionization in positive multiple reaction monitoring mode was used for detection. The method was validated over the concentration range 0.625-40 ng/mg. RESULTS: Using ten times less hair than in a previously published method, the lower limit of quantitation was validated at 0.625 ng/mg. The interday and intraday assay precision, expressed as the percentage coefficient of variation (CV), for spiked calibration standards and quality control samples was lower than 7% and accuracy ranged from 97 to 110%. For quality controls prepared from authentic hair the CV was less than 12%. The extraction efficiency for authentic quality control samples was determined to be 83% after repeated extractions of the same samples. CONCLUSIONS: This paper reports the first quantitative method for the determination of efavirenz in hair to be developed in South Africa. The validated method allowed for the successful monitoring of efavirenz in hair collected from HIV-infected patients as part of a clinical study.
RATIONALE: Drug levels in hair provide a longer window of detection, compared to plasma drug levels, and therefore hair analysis has the advantage of assessing adherence over a longer period of time. No methods for the analysis of antiretroviral drugs in hair currently exist in South Africa, and worldwide there is only one validated method for the determination of efavirenz in hair that has been published. METHODS:Efavirenz was extracted from 0.2 mg of hair through a simultaneous pulverization and extraction step. Separation was achieved on an Agilent Poroshell C18 column using an isocratic elution with a total run time of 3 min. A triple quadrupole mass spectrometer set to electrospray ionization in positive multiple reaction monitoring mode was used for detection. The method was validated over the concentration range 0.625-40 ng/mg. RESULTS: Using ten times less hair than in a previously published method, the lower limit of quantitation was validated at 0.625 ng/mg. The interday and intraday assay precision, expressed as the percentage coefficient of variation (CV), for spiked calibration standards and quality control samples was lower than 7% and accuracy ranged from 97 to 110%. For quality controls prepared from authentic hair the CV was less than 12%. The extraction efficiency for authentic quality control samples was determined to be 83% after repeated extractions of the same samples. CONCLUSIONS: This paper reports the first quantitative method for the determination of efavirenz in hair to be developed in South Africa. The validated method allowed for the successful monitoring of efavirenz in hair collected from HIV-infectedpatients as part of a clinical study.
Authors: Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange Journal: Expert Opin Pharmacother Date: 2007-04 Impact factor: 3.889
Authors: Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Louis Bernard; Albert Vuagnat; Gilles Peytavin; Marie-Charlotte Hallouin; Damien Bouhour; Thu Huyen Nguyen; Jean Louis Vildé; François Bricaire; Gilles Raguin; Pierre de Truchis; David Ghez; Michel Duong; Christian Perronne Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391
Authors: Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Audrey L French; Marla J Keller; Michael H Augenbraun; Stephen J Gange; Chenglong Liu; Wendy J Mack; Monica Gandhi Journal: PLoS One Date: 2015-06-08 Impact factor: 3.240
Authors: Jenna Johnston; Lubbe Wiesner; Peter Smith; Gary Maartens; Catherine Orrell Journal: South Afr J HIV Med Date: 2019-04-29 Impact factor: 2.744